Dane Leone
Stock Analyst at Raymond James
(1.51)
# 2,539
Out of 4,667 analysts
88
Total ratings
33.33%
Success rate
-8.18%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.94 | +324.99% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $9.63 | +367.29% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $94.81 | +5.47% | 9 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $57.07 | -47.43% | 1 | Nov 16, 2023 | |
| BLUE bluebird bio | Maintains: Outperform | $10 → $13 | $0.30 | +4,190.43% | 6 | Nov 8, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $743.35 | +27.80% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.50 | +420.00% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $23.04 | +99.65% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $25.64 | +169.11% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $4.66 | +522.32% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $8 | $1.37 | +483.94% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $8.78 | +59.45% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $23.72 | +144.52% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $27.58 | +153.81% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.05 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $49.86 | +26.35% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $57.88 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.70 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $46.58 | +39.54% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.91 | - | 5 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $287.87 | -11.42% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $5.36 | +497.01% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $153.11 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.94
Upside: +324.99%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $9.63
Upside: +367.29%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $94.81
Upside: +5.47%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $57.07
Upside: -47.43%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $10 → $13
Current: $0.30
Upside: +4,190.43%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $743.35
Upside: +27.80%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.50
Upside: +420.00%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $23.04
Upside: +99.65%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $25.64
Upside: +169.11%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $4.66
Upside: +522.32%
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $1.37
Upside: +483.94%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $8.78
Upside: +59.45%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $23.72
Upside: +144.52%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $27.58
Upside: +153.81%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.05
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $49.86
Upside: +26.35%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $57.88
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.70
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $46.58
Upside: +39.54%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $4.91
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $287.87
Upside: -11.42%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $5.36
Upside: +497.01%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $153.11
Upside: -